AI assistant
AGENUS INC — Director's Dealing 2023
Jan 9, 2023
34023_dirs_2023-01-09_e13bc8f0-674b-40e0-ada4-49d06c4469bf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGENUS INC (AGEN)
CIK: 0001098972
Period of Report: 2023-01-05
Reporting Person: O'Day Steven J (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-05 | Common Stock | A | 109381 | $2.45 | Acquired | 272384 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-05 | Stock Option | $2.45 | A | 200000 | Acquired | 2033-01-05 | Common Stock (200000) | Direct |
Footnotes
F1: Reflects the executive's 2022 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.
F2: $2.45 was the fair market value of Agenus Common Stock on January 5, 2023, the stock issuance date.
F3: Option was granted on January 5, 2023 and awarded in accordance with the 2019 Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.